Insider buying
~$5.6K10K sh @ $0.562
8 days before an 8-KTraded Sep 14 · filed 1 day later
A Humacyte director paid $5.6K out of pocket for Humacyte shares. Shares held went up 25% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Aug 17, 2026 · Filed Aug 19, 2026
A Humacyte director paid $18K out of pocket for Humacyte shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$17,820
Shares × reported transaction price
<$25K
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
5 days after results of Aug 12, 2026, 85 days before results of Nov 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $0.5606 on Aug 17, 2026, within 2% of its 52-week low, after a 27% drop over the previous 30 trading days
52-week range $0.55 (Aug 13, 2026) to $2.48 (Oct 6, 2025), 1% of the way up, from 251 adjusted closes. 30 trading days earlier: $0.7706 on Jul 6, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Keith Anthony Jones's first open-market purchase of HUMA in filings since 2021
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.7% | +1.1% | +0.6% |
| 30 days | −13.4% | +1.4% | −14.8% |
Past results only. Not a forecast.
Insider buying
8 days before an 8-KTraded Sep 14 · filed 1 day later
A Humacyte director paid $5.6K out of pocket for Humacyte shares. Shares held went up 25% with this purchase.
Insider buying
Traded Aug 20 · filed 1 day later
A Humacyte director paid $6.9K out of pocket for Humacyte shares. Shares held went up 33% with this purchase.
Insider filing
Traded Jun 11 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Keith Anthony Jones, Director's past purchases, 30 days after disclosure: 3 buys, median −15.1 pts vs S&P 500, beat it 0 of 3 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.